Persistent hyperinsulinaemic hypoglycaemia of infancy (PHHI) is a heterogeneous disorder characterized by profound hypoglycaemia due to inappropriate hypersecretion of insulin. An important diagnostic goal is to distinguish patients with a focal hyperplasia of islet cells of the pancreas (FoPHHI) from those with a diffuse abnormality of islets (DiPHHI), because the management differs significantly. The intriguing similarity between islet cell hyperplasia and tumourigenesis prompted us to investigate whether the imprinted genes in the 11p15 region are involved. Results showed that diffuse forms are caused by constitutional homozygous or compound heterozygous mutations of the SUR1 gene. In contrast, focal forms are caused by loss of the maternally inherited 11p15 region, resulting in both loss of the maternally expressed tumour suppressor genes accounting for hyperplasia and somatic reduction to hemizygosity or homozygosity of the paternally inherited SUR1, limited to the lesion. Thus, this somatic disorder, which leads both to β-cell proliferation and to hyperinsulinism, can be considered the somatic equivalent, restricted to a microscopic focal lesion, of constitutional uniparental disomy associated with unmasking of a heterozygous parental mutation.

Keywords:
Alleles, loss, Beckwith-Wiedemann syndrome, Neonatal hypoglycaemia, Persistent hyperinsulinism, Potassium-ATP channel
1.
Bruining G: Recent advances in hyperinsulinism and the pathogenesis of diabetes mellitus. Curr Opin Pediatr 1990;2:758–765.
2.
Shilyansky J, Fisher S, Cutz E, Perlman K, Filler R: Is 95% pancreatectomy the procedure of choice for treatment of persistent hyperinsulinemic hypoglycemia of the neonate? J Pediatr Surg 1997;32:342–346.
3.
Nestorowicz A, Wilson BA, Schoor KP, Inoue H, Glaser B, Landau H, Stanley CA, Thornton PS, Clement JP 4th, Bryan J, Aguilar-Bryan L, Permutt MA: Mutations in the sulfonylurea receptor gene are associated with familial hyperinsulism in Ashkenazi Jews. Hum Mol Genet 1996;5:1813–1822.
4.
Thomas PM, Cote GJ, Wohllk N, Haddad B, Mathew PM, Rabl W, Aguilar Bryan L, Gagel RF, Bryan J: Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 1995;268:426–429.
5.
Thomas PM, Wohllk N, Huang E, Kuhnle U, Rabl W, Gagel RF, Cote GJ: Inactivation of the first nucleotide-binding fold of the sulfonylurea receptor, and familial persistent hyperinsulinemic hypoglycemia of infancy. Am J Hum Genet 1996;59:510–518.
6.
Thomas P, Ye Y, Lightner E: Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum Mol Genet 1996;5:1809–1812.
7.
Nestorowicz A, Inagaki N, Gonoi T, Schoor K, Wilson B, Glaser B, Landau H, Stanley C, Thornton P, Seino S, Permutt M: A nonsense mutation in the inward rectifier potassium channel gene, Kir6.2, is associated with familial hyperinsulinism. Diabetes 1997;46:1743–1748.
8.
Stanley CA, Lieu YK, Hsu BY, Burlina AB, Greenberg CR, Hopwood NJ, Perlman K, Rich BH, Zammarchi E, Poncz M: Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N Engl J Med 1998;338:1352–1357.
9.
Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, Stanley C, Thornton P, Permutt A, Matschinsky F, Herold K: Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 1998;338:226–230.
10.
Goossens A, Gepts W, Saudubray J, Bonnefont J, Nihoul-Fékété C, Heitz P, Kloppel G: Diffuse and focal nesidioblastosis: A clinicopathological study of 24 patients with persistent neonatal hyperinsulinemic hypoglycemia. Am J Surg Pathol 1989;13:766–775.
11.
Jaffé R, Hashida Y, Yunis E: Pancreatic pathology in hyperinsulinemic hypoglycemia of infancy. Lab Invest 1980;42:356–365.
12.
Rahier J, Sempoux C, Fournet J-C, Poggi F, Brunelle F, Nihoul-Fékété C, Saudubray J-M, Jaubert F: Partial or near-total pancreatectomy for persistent neonatal hyperinsulinemic hypoglycemia: The pathologist’s contribution. Histopathology 1998;32:15–19.
13.
Junien C: Beckwith-Wiedemann syndrome, tumorigenesis and imprinting. Curr Opin Genet Dev 1992;2:431–438.
14.
Giannoukakis N, Deal C, Paquette J, Goodyer C, Polychronakos C: Parental genomic imprinting of the human IGF2 gene. Nat Genet 1993;4:98–101.
15.
Lee MP, Hu R-J, Johnson LA, Feinberg AP: Human KVLQT1 gene shows tissue-specific imprinting and encompasses Beckwith-Wiedemann syndrome chromosomal rearrangements. Nat Genet 1997;15:181–185.
16.
Matsuoka S, Edwards M, Bai C, Parker S, Zhang P, Baldini A, Harper J, Elledge S: p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995;9:650–662.
17.
Zhang Y, Tycko B: Monoallelic expression of the human H19 gene. Nat Genet 1992;1:40–44.
18.
Hao Y, Crenshaw T, Moulton T, Newcomb E, Tycko B: Tumour-suppressor activity of H19 RNA. Nature 1993;365:764–767.
19.
Hatada I, Inazawa J, Abe T, Nakayama M, Kaneko Y, Jinno Y, Niikawa N, Ohashi S, Fukushima Y, Iida K, Yutani C, Takahashi S, Chiba Y, Ohishi S, Mukai T: Genomic imprinting of human p57KIP2 and its reduced expression in Wilms’ tumors. Hum Mol Genet 1996;5:783–788.
20.
Guillemot F, Caspary T, Tilghman SM, Copeland NG, Gilbert DJ, Jenkins NA, Anderson DJ, Joyner AL, Rossant J, Nagy A: Genomic imprinting of Mash2, a mouse gene required for trophoblast development. Nat Genet 1995;9:235–242.
21.
Ohlsson R, Nystrom A, Pfeifer-Ohlsson S, Tohonen V, Hedborg F, Schofield P, Flam F, Ekström T: IGF2 is parentally imprinted during human embryogenesis and in the Beckwith-Wiedemann syndrome. Nat Genet 1993;4:94–97.
22.
Yuan L, Qian N, Tycko B: An extended region of biallelic gene expression and rodent-human synteny downstream of the imprinted H19 gene on chromosome 11p15.5. Hum Mol Genet 1996;5:1931–1937.
23.
Steenman M, Rainier S, Dobry C, Grundy P, Horon I, Feinberg A: Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilm’s tumour. Nat Genet 1994;7:433–439.
24.
Dubois J, Brunnelle F, Touati G, Sebag G, Nuttin C, Thach T, Nihoul-Fékété C, Rahier J, Saudubray J: Hyperinsulinism in children: Diagnostic value of pancreatic venous sampling correlated with clinical, pathological and surgical outcome in 25 cases. Pediatr Radiol 1995;25:512–516.
25.
Aguilar-Bryan L, Nichols C, Wechsler S, Clemen TJ, Boyd A, Gonzalez G, Herrera Sosa H, Nguy K, Bryan J, Nelson D: Cloning of the beta cell high-affinity sulfonylurea receptor: A regulator of insulin secretion. Science 1995;268:423–426.
26.
Inagaki N, Inazawa J, Seino S: cDNA sequence, gene structure, and chromosomal localization of the human ATP sensitive potassium channel, uKATP-1, gene. Genomics 1995;30:102–104.
27.
Kane C, Shepherd RM, Squires PE, Johnson PRV, James RFL, Milla PJ, Aynsley-Green A, Lindley KJ, Dunne MJ: Loss of functional KATP channels in pancreatic β-cells causes persistent hyperinsulinemic hypoglycemia of infancy. Nat Med 1996;2:1344–1347.
28.
Reik W, Brown KW, Schneid H, Le Bouc Y, Bickmore W, Maher ER: Imprinting mutations in the Beckwith-Wiedemann syndrome suggested by altered imprinting pattern in the IGF2-H19 domain. Hum Mol Genet 1995;4:2379–2385.
29.
Rahier J: Relevance of endocrine pancreas nesidioblastosis to hyperinsulinemic hypoglycemia. Diabetes Care 1989;12:164–166.
30.
Ledbetter DH, Engel E: Uniparental disomy in humans: Development of an imprinting map and its implications for prenatal diagnosis. Hum Mol Genet 1995;4:1757–1764.
31.
Sempoux C, Poggi F, Brunelle F, Saudubray J, Fékété C, Rahier J: Nesidioblastosis and persistent neonatal hyperinsulinism. Diabète Métab 1995;21:402–407.
32.
Brasier J, Henske E: Loss of the polycystic kidney disease (PKD1) region of chromosome 16p13 in renal cyst cells supports a loss-of-function model for cyst pathogenesis. J Clin Invest 1997;99:194–199.
33.
Lyonnet S, Bonnefont J-P, Saudubray J-M, Nihoul-Fékété C, Brunelle F: Localization of focal lesion permitting partial pancreatectomy in infants. Lancet 1989;ii:671.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.